tirzepatide facebook Medscape - The SURPASS-PEDS trial shows delivers durable glycemic control and weight benefit in youth with type 2 diabetes, the first therapy to show this effect. http://ms.spr.ly/6180sWS1i Tirzepatide - Image Essentials Weight

FDA has documented over 400 adverseevent reports with compounded semaglutide and 300 with compounded tirzepatide, though the Alliance for Pharmacy Compounding disputes the reliability of those data

The post describes GIP receptor activation as enhancing insulin secretion and reducing appetite through neural pathways distinct from GLP-1, which is why tirzepatide is called a dual agonist rather than a single-target one

For example, one person might find that a dosage of 0.5 mg works well for them, while another person may need a higher dose, up to 2 mg per week

Yes, but its best if someone helps

The topline results from the ESSENCE trial of semaglutide showed that a once-weekly 2.4mg dose of the drug was better than placebo at resolving MASH and improving liver fibrosis, meeting its primary efficacy objectives